Headlines about Amphastar Pharmaceuticals (NASDAQ:AMPH) have been trending somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.8852704470478 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have effected Accern’s rankings:
- ETFs with exposure to Amphastar Pharmaceuticals, Inc. : September 12, 2017 (finance.yahoo.com)
- Stock on Hold Line: Amphastar Pharmaceuticals, Inc. (AMPH) – Street Observer (press release) (streetobserver.com)
- Comparing Merck & (MRK) & Amphastar Pharmaceuticals (AMPH) (americanbankingnews.com)
- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Experiences Light Trading Volume – First News 24 (firstnewspaper24.com)
- Amphastar Pharmaceuticals, Inc. (AMPH) is at $15.54 per share and Corium International, Inc. (CORI) is listed at $9.08 – Stocks Gallery (stocksgallery.com)
A number of brokerages have commented on AMPH. ValuEngine downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $19.00 target price (down from $20.00) on shares of Amphastar Pharmaceuticals in a research note on Friday, August 11th. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $19.00 price target on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Finally, BMO Capital Markets reiterated a “hold” rating and set a $16.00 price target on shares of Amphastar Pharmaceuticals in a research report on Monday, July 31st. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.86.
Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) opened at 15.79 on Tuesday. The firm’s 50 day moving average is $15.87 and its 200-day moving average is $15.80. The firm has a market capitalization of $729.42 million, a PE ratio of 205.06 and a beta of 1.66. Amphastar Pharmaceuticals has a 12 month low of $12.05 and a 12 month high of $21.75.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.05. The business had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a net margin of 1.61% and a return on equity of 2.42%. The company’s revenue was down 4.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.23 EPS. On average, analysts expect that Amphastar Pharmaceuticals will post $0.27 EPS for the current fiscal year.
Amphastar Pharmaceuticals declared that its Board of Directors has authorized a stock buyback program on Wednesday, August 9th that authorizes the company to buyback $20.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its stock is undervalued.
In other news, Director Richard K. Prins sold 10,000 shares of the stock in a transaction dated Tuesday, August 15th. The shares were sold at an average price of $14.81, for a total transaction of $148,100.00. Following the transaction, the director now directly owns 33,844 shares in the company, valued at approximately $501,229.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction dated Monday, August 14th. The stock was sold at an average price of $14.80, for a total transaction of $74,000.00. Following the transaction, the director now owns 33,844 shares in the company, valued at $500,891.20. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Amphastar Pharmaceuticals (AMPH) Stock Price” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://sportsperspectives.com/2017/09/12/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-amphastar-pharmaceuticals-amph-stock-price.html.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.